News

Enlarge image

ResearchEUGermanyFrance

Sequencing traces TB outbreaks

14.02.2013 - EU researchers have prooved next generation sequencing to be more effective in tracing tuberculosis outbreaks than the current gold standard.

A new form of genetic testing of the bacteria that cause tuberculosis (TB) can provide better information on TB transmission and also trace TB outbreaks more accurately than the current gold standard test, according to results from the EU’s €7.8m PathoNGen-Trace project (PLOS Medicine).

A team of researchers led by Stefan Niemann including the SMEs Ridom GmbH (Muenster) and Genoscreen SAS (Lille) compared the results of next-generation sequencing and genotyping on 86 Mycobacterium tuberculosis isolates from a TB outbreak in Germany between 1997 and 2010, in which 2301 people became ill. They found that sequencing provided more accurate information on clustering and longitudinal spread of the pathogen than the standard test (genotyping). Importantly, whole genome sequencing revealed that first outbreak isolates were falsely clustered by classical genotyping and do not belong to one recent transmission chain.

By using whole genome sequencing, the authors estimated that the genetic material of M. tuberculosis evolved at a rate at 0.4 mutations per genome per year, suggesting that the bacterium grows in its natural host (infected people) with a doubling time of 22 hours, or 400 generations per year. This finding about the evolution of M. tuberculosis indicates how information from whole genome sequencing can be used to help trace future outbreaks

As the costs of whole genome sequencing are declining, this test could soon become the standard method for identifying transmission patterns and rates of infectious disease outbreaks, say the authors. "We envision that progressive effective implementation will be accelerated by the continuously decreasing sequencing costs, broader distribution of so-called bench top next generation sequencers, and upcoming bioinformatics developments to facilitate quick and relevant interpretation of the resulting data in public health and medical contexts." PathoNGen-Trace had been kicked-off in March 2012.

© eurobiotechnews.eu/tg 

http://www.european-biotechnology-news.com/news/news/2013-01/sequencing-traces-tb-outbreaks.html

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Nuclear medicineNorwayFrance

28.06.2016 Nordic Nanovector has teamed up with Areva Med to develop a treatment for leukaemia. The compound in question is a lead-212 conjugated anti-CD37 antibody.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN (D)1.50 EUR12.78%
  • BIOCARTIS GROUP NV (B)7.57 EUR7.53%
  • SWEDISH ORPHAN BIOVITRUM (S)13.11 USD6.59%

FLOP

  • NICOX (F)11.57 EUR-8.61%
  • KAROLINSKA (S)7.55 SEK-4.43%
  • AB SCIENCE (F)14.20 EUR-4.05%

TOP

  • PROTHENA PLC (IE)53.17 USD31.1%
  • THERAMETRICS (CH)0.05 CHF25.0%
  • FLAMEL TECHNOLOGIES (F)12.49 USD24.9%

FLOP

  • MOLOGEN (D)1.50 EUR-40.2%
  • ALLERGY THERAPEUTICS (UK)19.50 GBP-21.2%
  • SAREUM HOLDINGS (UK)0.64 GBP-21.0%

TOP

  • KARO BIO (S)28.70 SEK1693.8%
  • NICOX (F)11.57 EUR515.4%
  • SAREUM HOLDINGS (UK)0.64 GBP156.0%

FLOP

  • BB BIOTECH (D)45.22 EUR-84.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.64 SEK-79.6%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 22.07.2016